View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 30, 2018updated 29 Mar 2018 11:06am

Deals and M&As this week: TELA Bio, Polarean Imaging, Cesca Therapeutics

TELA Bio Inc has agreed to raise $1m in a venture financing round led by ProMedica’s ProMedica Innovations Venture Fund.

TELA Bio Inc has agreed to raise $1m in a venture financing round led by ProMedica’s ProMedica Innovations Venture Fund.

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

TELA Bio and ProMedica Innovations will form a strategic partnership with surgical specialists at the ProMedica Hernia Center, as part of the agreement.

TELA Bio plans to use the proceeds towards the enhancement of patient care, surgical outcomes and cost reductions.

Based in the US, TELA Bio is a provider of surgical reconstruction solutions, while ProMedica, also based in the US, is a network of hospitals and healthcare centres.

Polarean Imaging Ltd has raised £3m ($4.2m) through an initial public offering of shares of its common stock.

The proceeds from the offering will be used to fund clinical trials, develop technology and for working capital purposes.

Based in the UK, Polarean is a manufacturer and service provider for noble gas polariser devices and ancillary instruments.

“Accelerate Diagnostics Inc plans to raise $150m through a private placement of 2.5% convertible senior notes due March 2023.”

Cesca Therapeutics Inc plans to raise $1.38m through the private placement of 609,636 shares of its common stock priced at $2.27 a share.

Investors will also receive unregistered warrants to purchase 304,818 shares of common stock priced at $2.68 a share.

Based in the US, Cesca is a developer and manufacturer of automated blood processing systems and disposables.

Tristel plc has signed a manufacturing and marketing agreement with Parker Laboratories to manufacture and market its Tristel’s Duo chlorine dioxide foam disinfectant in the North, Central and South America regions.

The collaboration will enable the two companies to enter the ultrasound and infection prevention market in the US.

Based in the UK, Tristel is involved in the manufacturing of infection prevention and contamination control products, while Parker Laboratories is a US-based company involved in the development and manufacturing of products for use in ultrasound and electromedical markets.

Akers Biosciences Inc (Akers) has signed a three-year national distribution agreement with Diagnostica Stago Inc for the sale of its PIFA PLUSS PF4 Rapid Assay across the US.

PIFA PLUSS PF4 Rapid Assay is an in-vitro diagnostic device for testing Heparin-induced thrombocytopenia (HIT).

Based in the US, Akers is a medical device company, while Diagnostica Stago, also based in the US, is a provider of in-vitro diagnostic products.

AroCell AB has raised SEK35m ($4.24m) through a rights offering of 10.75 million shares priced at SEK3.3 ($0.39) a share.

Each shareholder will receive one subscription right, which grants the holder to purchase new shares.

Based in Sweden, AroCell AB is involved in the development and commercialisation of tests for cancer diagnosis and monitoring.

Accelerate Diagnostics Inc plans to raise $150m through a private placement of 2.5% convertible senior notes due March 2023.

Based in the US, Accelerate Diagnostics is an in-vitro diagnostics company providing solutions for the diagnosis of serious infections.

The company plans to use the funds for general corporate purposes, working capital and acquisitions.

3B Medical Inc has completed the acquisition of US-based research and development company VBOX.

Through the acquisition, 3B Medical gains the global licensing rights to VBOX’s intellectual property, including a light portable oxygen concentrator.

Based in the US, 3B Medical focuses on the development of innovative solutions in sleep and respiratory therapy.

RadiaDyne Inc has sold its OARtrac patient dose monitoring system to University Hospital’s Cleveland Medical Center (UH).

OARtrac system is a diagnostic patient dose monitoring platform used in cancer treatment.

Based in the US, RadiaDyne is a privately held diagnostic and medical device company focused on patient dose monitoring technology, while UH, also based in the US, is a non-profit organisation.

Etymotic Research Inc has merged with US-based medical device company Lucid Hearing.

Based in the US, Etymotic is involved in the research, development and manufacturing of high-fidelity headsets and earphones to enhance and protect hearing.

The merger will enable Etymotic Research to develop new products.

Related Companies

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network